Histologic scoring indices for evaluation of disease activity in ulcerative colitis.

BACKGROUND Disease activity can be determined using clinical, endoscopic or histologic criteria in patients with ulcerative colitis (UC). Persistent disease activity is associated with poor outcomes. Histologic disease activity has been shown to be associated with relapse, colectomy and colorectal cancer. The ability to objectively evaluate microscopic disease activity using histology is important for both clinical practice and clinical trials. However, the operating properties of the currently available histologic indices remain unclear. OBJECTIVES A systematic review was undertaken to identify and evaluate the development and operating characteristics of histologic disease activity indices used to assess disease activity in people with ulcerative colitis. SEARCH METHODS We searched MEDLINE, EMBASE, PubMed, CENTRAL and the Cochrane IBD Review Group Specialized Trials Register from inception to 2 December 2016 for applicable studies. There were no language or document type restrictions. SELECTION CRITERIA Any study design (e.g. randomized controlled trials, cohort studies, case series) that evaluated a histologic index in patients with UC were considered for inclusion. Eligible patients were adults (> 18 years), diagnosed with UC using conventional clinical, radiographic, endoscopic and histologic criteria. DATA COLLECTION AND ANALYSIS Two authors (MHM and CEP) independently reviewed the titles and abstracts of the studies identified from the literature search. A standardized form was used to assess eligibility of trials for inclusion and for data extraction.Two authors (MHM and CEP) independently extracted and recorded data, which included the number of patients enrolled, number of patients per treatment arm, patient characteristics including age and gender distribution, and the name of the histologic index. Outcomes (i.e. intra-rater reliability, inter-rater reliability, internal consistency, content validity, criterion validity, construct validity, responsiveness, and feasibility) were recorded for each trial. MAIN RESULTS In total, 126 reports describing 30 scoring indices were identified through the screening process. Eleven of the 30 scoring indices have undergone some form of index validation. Intra-rater reliability was assessed for eight scoring indices. Inter-rater reliability was evaluated for all 11 of the scoring indices. Three of the indices underwent content validation. Two of the included scoring indices assessed criterion validity. Six of the included scoring indices explored content validity. Two of the included scoring indices were tested for responsiveness. AUTHORS' CONCLUSIONS The Nancy Index and the Robarts Histopathology Index have undergone the most validation in that four operating properties including reliability, content validity, construct validity (hypothesis testing) and criterion validity have been tested. However, none of the currently available histologic scoring indices have been fully validated. In order to determine the optimal endpoint for histologic healing in UC, more research is required. The optimal index would need to be fully validated.

[1]  R. Kiesslich,et al.  Development and reliability of the new endoscopic virtual chromoendoscopy score: the PICaSSO (Paddington International Virtual ChromoendoScopy ScOre) in ulcerative colitis. , 2017, Gastrointestinal endoscopy.

[2]  N. Khan,et al.  Treat to Target in Inflammatory Bowel Disease: An Updated Review of Literature , 2017, Current Treatment Options in Gastroenterology.

[3]  S. Vermeire,et al.  Tu1943 Validation of the Simplified Geboes Score for Ulcerative Colitis , 2016 .

[4]  S. Osawa,et al.  The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. , 2016, Journal of Crohn's & colitis.

[5]  J. Jung,et al.  Correlation between Histological Activity and Endoscopic, Clinical, and Serologic Activities in Patients with Ulcerative Colitis , 2015, Gastroenterology research and practice.

[6]  M. Silverberg,et al.  Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease , 2015, Inflammatory bowel diseases.

[7]  S. Travis,et al.  Endoscopic Disease Activity in Inflammatory Bowel Disease , 2015, Current Gastroenterology Reports.

[8]  S. Ladelund,et al.  Level of Fecal Calprotectin Correlates With Endoscopic and Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative Colitis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  L. Stitt,et al.  Development and validation of a histological index for UC , 2015, Gut.

[10]  S. Travis,et al.  Development and validation of the Nancy histological index for UC , 2015, Gut.

[11]  A. Wiernicka,et al.  Histological healing after infliximab induction therapy in children with ulcerative colitis. , 2015, World journal of gastroenterology.

[12]  G. delle Fave,et al.  Application of clinical indexes in ulcerative colitis patients in regular follow-up visit: correlation with endoscopic 'mucosal healing' and implication for management. Preliminary results. , 2015, European Review for Medical and Pharmacological Sciences.

[13]  K. Farkas,et al.  Is mucosal healing more common than clinical remission in ulcerative colitis? – Is it the truth or only a myth coming from the studies? , 2015, Scandinavian journal of gastroenterology.

[14]  Y. Kohgo,et al.  Su1705 Quantification of Autofluorescence Imaging Is Useful for Objectively Assessing the Severity of Ulcerative Colitis , 2015 .

[15]  T. Tomita,et al.  Su1242 Serum Reg Iα Is a Marker to Predict Histological and Clinical Activity in Ulcerative Colitis , 2015 .

[16]  M. Silverberg,et al.  593 Predictive Value of Basal Plasmacytosis on Clinical Relapse in Quiescent Ulcerative Colitis , 2015 .

[17]  C. Taxonera,et al.  Tu1113 Endoscopic and Histologic Remission Correlation With Biomarkers in UC Patients Treated With Adalimumab , 2015 .

[18]  Christopher R. Cabanski,et al.  Su1220 Rectal Bleeding Accurately Reflects Level of Mucosal Inflammation in Patients With Ulcerative Colitis , 2015 .

[19]  H. Ogata,et al.  Su2031 Evaluation of Severity Using Endoscopic Dual Red Imaging Targeting Submucosal Vessel in Patients With Ulcerative Colitis , 2015 .

[20]  S. Vermeire,et al.  Su1212 A Simplified Histological Geboes Score for Ulcerative Colitis , 2015 .

[21]  J. Langhorst,et al.  Su1235 Monitoring of Histologically Defined Healing in Ulcerative Colitis: Performance of Fecal Lactoferrin, Calprotectin, PMN-Elastasis and CRP and WBC Compared to the Riley Score , 2015 .

[22]  G. Kaplan,et al.  Tu1219 Clinical Outcome of Ulcerative Colitis Patients With Complete Mucosal Healing but With Subtle Abnormalities Detected by Novel iSCAN Endoscopic , 2015 .

[23]  F. Zerbib,et al.  Tu1339 Mucosal and Histologic Response to Cyclosporin in Ulcerative Colitis: A Cohort Study , 2015 .

[24]  G. Kaplan,et al.  Complete mucosal healing defined by endoscopic Mayo subscore still demonstrates abnormalities by novel high definition colonoscopy and refined histological gradings , 2015, Endoscopy.

[25]  A. Tursi,et al.  Histological inflammation in ulcerative colitis in deep remission under treatment with infliximab. , 2014, Clinics and research in hepatology and gastroenterology.

[26]  A. Bitton,et al.  The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients. , 2014, Journal of Crohn's & colitis.

[27]  S. Vermeire,et al.  Development of a Simplified histological Geboes Score for ulcerative colitis , 2015 .

[28]  P. Siersema,et al.  Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. , 2015, Journal of Crohn's & Colitis.

[29]  Rubin David,et al.  O-001 Budesonide MMX® 9 mg for Inducing Remission in Patients With Mild-to-Moderate Ulcerative Colitis Not Adequately Controlled With Oral 5-ASAs , 2014 .

[30]  W. Hong,et al.  P-102 Histologic Activity After Induction Therapy with Multimatrix Mesalamine Is Associated with 12-Month Remission Status in Ulcerative Colitis , 2014 .

[31]  S. Travis,et al.  Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. , 2014, Journal of Crohn's & colitis.

[32]  F. Rizzello,et al.  Inter-observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). , 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[33]  Michael Joseph Peterson,et al.  Reproducibility of histological assessments of disease activity in UC , 2014, Gut.

[34]  T. Voiosu,et al.  Evaluation of histologic features with potential prognostic value in ulcerative colitis. , 2014, Romanian journal of internal medicine = Revue roumaine de medecine interne.

[35]  J. Salleron,et al.  Comparing histological activity indexes in UC , 2014, Gut.

[36]  G. D'Haens,et al.  A Systematic Review of the Measurement of Endoscopic Healing in Ulcerative Colitis Clinical Trials: Recommendations and Implications for Future Research , 2014, Inflammatory bowel diseases.

[37]  Elizabeth R. Paine,et al.  Colonoscopic evaluation in ulcerative colitis , 2014, Gastroenterology report.

[38]  L. Stitt,et al.  Sa1196 Responsiveness of Endoscopic Indices in the Evaluation of Ulcerative Colitis , 2014 .

[39]  K. Chayama,et al.  Tu1521 Correlation Between Endocytoscopy and Histopathological Activity in the Remission Stage of Ulcerative Colitis: a Pilot Study , 2014 .

[40]  D. Rubin,et al.  Sa1213 Assessment of the Degree of Variation of Histologic Inflammation in Ulcerative Colitis , 2014 .

[41]  C. Hassan,et al.  Second-generation colon capsule endoscopy vs. colonoscopy in pediatric ulcerative colitis: a pilot study , 2014, Endoscopy.

[42]  L. Stitt,et al.  P150 Responsiveness of endoscopic indices in the evaluation of ulcerative colitis , 2014 .

[43]  M. Peterson,et al.  P284 Agreement of central readers in the evaluation of histopathological disease activity in ulcerative colitis , 2014 .

[44]  F. Rizzello,et al.  P452 Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program , 2014 .

[45]  A. Wiernicka,et al.  P440 Influence of induction therapy with infliximab on histological changes in children with ulcerative colitis – preliminary data , 2014 .

[46]  W. Sandborn,et al.  Feasibility of Endoscopic Assessment and Treating to Target to Achieve Mucosal Healing in Ulcerative Colitis , 2014, Inflammatory bowel diseases.

[47]  E. Markova,et al.  EVALUATION OF HISTOLOGICAL PARAMETERS IN PATIENTS WITH CLINICAL REMISSION OF ULCERATIVE COLITIS , 2014 .

[48]  D. Rubin,et al.  Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[49]  D. Altman,et al.  Reliability and initial validation of the ulcerative colitis endoscopic index of severity. , 2013, Gastroenterology.

[50]  A. Cheifetz,et al.  Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[51]  P. Rutgeerts,et al.  The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. , 2013, Gastroenterology.

[52]  P. Rutgeerts,et al.  Correlation Between the Endoscopic and Histologic Score in Assessing the Activity of Ulcerative Colitis , 2013, Inflammatory bowel diseases.

[53]  W. Sandborn,et al.  Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study , 2013, Gut.

[54]  S. Robson,et al.  Predictors of Endoscopic Inflammation in Patients With Ulcerative Colitis in Clinical Remission , 2013, Inflammatory bowel diseases.

[55]  G. Kaplan,et al.  P112 iSCAN-High definition colonoscopy correlates with white light endoscopy and histology assessment in mucosal healing for ulcerative colitis , 2013 .

[56]  A. Zinsmeister,et al.  Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[57]  H. Miwa,et al.  Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis , 2012, Journal of gastroenterology and hepatology.

[58]  M. Neurath,et al.  Ulcerative colitis: UCCIS—a reproducible tool to assess mucosal healing , 2012, Nature Reviews Gastroenterology &Hepatology.

[59]  D. Rubin,et al.  Correlation Between Clinical, Endoscopic, and Histologic Disease Activity in Ulcerative Colitis: 1712 , 2012 .

[60]  A. Gasbarrini,et al.  Propionyl-L-carnitine hydrochloride for treatment of mild to moderate colonic inflammatory bowel diseases. , 2012, World journal of gastroenterology.

[61]  F. Rizzello,et al.  OC.12.1 INTEROBSERVER AGREEMENT IN IBD SCORES REQUIRES EXPERTISE AND EDUCATION: PRELIMINARY RESULTS FROM AN ONGOING IG-IBD STUDY , 2012 .

[62]  E. Kuipers,et al.  Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation , 2011, Inflammatory bowel diseases.

[63]  B. Sands,et al.  Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials? , 2011, Inflammatory bowel diseases.

[64]  E. Jung,et al.  Comparison between quantitative assessment of bowel wall vascularization by contrast-enhanced ultrasound and results of histopathological scoring in ulcerative colitis , 2012, International Journal of Colorectal Disease.

[65]  R. Kiesslich,et al.  Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease , 2011, Gut.

[66]  L. Kupčinskas,et al.  Randomised clinical trial: the efficacy and safety of propionyl‐l‐carnitine therapy in patients with ulcerative colitis receiving stable oral treatment , 2011, Alimentary pharmacology & therapeutics.

[67]  D. Altman,et al.  Translational Gastroenterology , 2011 .

[68]  G. Porro,et al.  Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[69]  H. Ogata,et al.  In Vivo Visualization and Evaluation of Colorectal Inflammation in Ulcerative Colitis by a Newly Integrated Endocytoscopy , 2011 .

[70]  Jun Kato,et al.  Is sigmoidoscopy sufficient for evaluating inflammatory status of ulcerative colitis patients? , 2011, Journal of gastroenterology and hepatology.

[71]  S. Travis,et al.  Depth of remission may not predict outcome of UC over 2 years , 2011, Gut.

[72]  E. Szigethy,et al.  Inflammatory bowel disease. , 2011, Pediatric clinics of North America.

[73]  F. Nagy,et al.  Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. , 2010, Journal of Crohn's & colitis.

[74]  C. Brensinger,et al.  M1227 Which Endoscopic or Clinical Factor is Most Predictive of Future Disease Course in Patients With Ulcerative Colitis , 2010 .

[75]  H. Ogata,et al.  Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients , 2010, Journal of Gastroenterology.

[76]  T. Ohkusa,et al.  Comparison of several activity indices for the evaluation of endoscopic activity in UC: Inter‐ and intraobserver consistency , 2010, Inflammatory bowel diseases.

[77]  G. Gasbarrini,et al.  Clinical trial: oral colon‐release parnaparin sodium tablets (CB‐01‐05 MMX®) for active left‐sided ulcerative colitis , 2010, Alimentary pharmacology & therapeutics.

[78]  T. Matsui,et al.  VALIDITY OF ACTIVITY INDICES IN ULCERATIVE COLITIS: COMPARISON OF CLINICAL AND ENDOSCOPIC INDICES , 2010, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

[79]  L. Peyrin-Biroulet,et al.  Clinical implications of mucosal healing for the management of IBD , 2010, Nature Reviews Gastroenterology &Hepatology.

[80]  P. Renzulli,et al.  Ulcerative colitis: Correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C‐reactive protein, and blood leukocytes , 2009, Inflammatory bowel diseases.

[81]  S. Cucchiara,et al.  PA29 EFFECTIVENESS OF A RECTAL INFUSION OF LACTOBACILLUS REUTERI ATCC 55730 IN CHILDREN WITH DISTAL ACTIVE ULCERATIVE COLITIS , 2009 .

[82]  D. Altman,et al.  1049 Identification of Items to Be Included in An Ulcerative Colitis Endoscopic Index of Severity (UCEIS) , 2009 .

[83]  D. Altman,et al.  WHICH ACTIVITY INDEX FOR ULCERATIVE COLITIS? EVALUATION OF INTER-OBSERVER VARIATION IN CLINICAL, ENDOSCOPIC AND COMPOSITE INDICES , 2009 .

[84]  D. Altman,et al.  W1205 How Variable Is the Mayo Score Between Observers and Might This Affect Trial Recruitment or Outcome , 2009 .

[85]  A. Ensari,et al.  Quantitative endoscopic and histologic activity assessment of ulcerative colitis. , 2009, Acta gastro-enterologica Belgica.

[86]  D. Altman,et al.  P086 - Which activity index for ulcerative colitis (UC)? Evaluation of inter-observer variation in clinical, endoscopic and composite indices , 2009 .

[87]  D. Altman,et al.  P151 - How variable is the Mayo score between observers and might this affect trial recruitment or outcome? , 2009 .

[88]  N. Harpaz,et al.  Severity of Inflammation as a Predictor of Colectomy in Patients With Chronic Ulcerative Colitis , 2009, Diseases of the colon and rectum.

[89]  B. Warren,et al.  HOW MUCH AGREEMENT IS THERE BETWEEN HISTOLOGICAL, ENDOSCOPIC AND CLINICAL ASSESSMENTS OF REMISSION IN ULCERATIVE COLITIS? , 2009 .

[90]  T. Ohkusa,et al.  Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis , 2008, Journal of gastroenterology and hepatology.

[91]  I. Gorelov,et al.  Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial , 2008, Gut.

[92]  Tong Lu,et al.  Are endoscopic grading and scoring systems in inflammatory bowel disease the same? , 2008, Saudi medical journal.

[93]  A. Staiano,et al.  Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[94]  Q. Ouyang,et al.  A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. , 2008, World Journal of Gastroenterology.

[95]  N. Harpaz,et al.  Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. , 2007, Gastroenterology.

[96]  R. Petras,et al.  Pathology of inflammatory bowel disease. , 2007, Seminars in pediatric surgery.

[97]  M. Vatn,et al.  Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. , 2007, Gastroenterology.

[98]  D. Altman,et al.  Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation , 2007, Trials.

[99]  W. Sandborn,et al.  Inflammatory bowel disease: clinical aspects and established and evolving therapies , 2007, The Lancet.

[100]  Philippe Marteau,et al.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.

[101]  O. Maeda,et al.  Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis , 2006, Gut.

[102]  T. Ohkusa,et al.  CURRENT OPINION OF ACTIVITY INDEX FOR COLONOSCOPIC AND HISTOLOGICAL FINDINGS IN ULCERATIVE COLITIS :A PROPOSAL OF NEW ACTIVITY ASSESSMENT BY CUMULATIVE METHOD OF SEVEN POINTS SCORES , 2006 .

[103]  C. Hawkey,et al.  Rdp58 Is a Novel and Potentially Effective Oral Therapy for Ulcerative Colitis , 2005, Inflammatory bowel diseases.

[104]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[105]  M. Schwartz,et al.  Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis , 2005, Gut.

[106]  P. Xie,et al.  Characteristics and therapeutic efficacy of sulfasalazine in patients with mildly and moderately active ulcerative colitis. , 2005, World journal of gastroenterology.

[107]  O. Maeda,et al.  Predictors of a response to cyclosporine or leukocyte removal therapy in patients with refractory ulcerative colitis , 2005 .

[108]  M. Schwartz,et al.  Is Endoscopy Necessary for the Measurement of Disease Activity in Ulcerative Colitis? , 2005, The American Journal of Gastroenterology.

[109]  T. Ohkusa,et al.  Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: A randomized, controlled pilot trial with long-term follow-up , 2005, Scandinavian journal of gastroenterology.

[110]  L. Camellini,et al.  Proposal of a New Clinical Index Predictive of Endoscopic Severity in Ulcerative Colitis , 2001, Digestive Diseases and Sciences.

[111]  Anne Lavergne,et al.  Colonoscopy of acute colitis , 1994, Digestive Diseases and Sciences.

[112]  N. Greenberger,et al.  Proctocolitis unresponsive to conventional therapy , 1987, Digestive Diseases and Sciences.

[113]  D. W. Day,et al.  Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis , 1982, Digestive Diseases and Sciences.

[114]  B. Korelitz,et al.  Responses to drug therapy in ulcerative colitis , 1976, The American Journal of Digestive Diseases.

[115]  G. Zou Quantifying responsiveness of quality of life measures without an external criterion , 2005, Quality of Life Research.

[116]  A. Imaoka,et al.  Randomized placebo‐controlled trial assessing the effect of bifidobacteria‐fermented milk on active ulcerative colitis , 2004, Alimentary pharmacology & therapeutics.

[117]  L. Mortelmans,et al.  Evaluation of early treatment response and predicting the need for colectomy in active ulcerative colitis with 99mTc-HMPAO white blood cell scintigraphy. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[118]  L. Aabakken,et al.  Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis , 2004, BMC gastroenterology.

[119]  S. Hanauer Medical therapy for ulcerative colitis 2004. , 2004, Gastroenterology.

[120]  D. Jewell,et al.  Randomized, double‐blind, placebo‐controlled trial of oral aloe vera gel for active ulcerative colitis , 2004, Alimentary pharmacology & therapeutics.

[121]  Alastair Forbes,et al.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. , 2004, Gastroenterology.

[122]  Z. Halpern,et al.  Low-Dose Low-Molecular Weight Heparin (Enoxaparin) Is Effective as Adjuvant Treatment in Active Ulcerative Colitis: An Open Trial , 2001, Digestive Diseases and Sciences.

[123]  G. Mazzacca,et al.  Serum Transglutaminase Correlates with Endoscopic and Histopathologic Grading in Patients with Ulcerative Colitis , 2001, Digestive Diseases and Sciences.

[124]  N. Harpaz,et al.  Histological grading of disease activity in chronic IBD Inter- and intra-observer variation among pathologists with different levels of experience , 2003 .

[125]  F. Manguso,et al.  Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double‐blind placebo‐controlled study , 2002, Alimentary pharmacology & therapeutics.

[126]  D. Levine,et al.  A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis , 2002, American Journal of Gastroenterology.

[127]  S. Friis,et al.  Octreotide in patients with active ulcerative colitis treated with high dose corticosteroids (OPUS 1) , 2002, European journal of gastroenterology & hepatology.

[128]  R. Löfberg,et al.  Effect of Budesonide Enema on Remission and Relapse Rate in Distal Ulcerative Colitis and Proctitis , 2002, Scandinavian journal of gastroenterology.

[129]  R. Cohen Evolving medical therapies for ulcerative colitis , 2001, Current gastroenterology reports.

[130]  M. Stolte,et al.  Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses , 2001, Gut.

[131]  S. Bunn,et al.  Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. , 2001, Journal of pediatric gastroenterology and nutrition.

[132]  P. Munkholm,et al.  An open-labeled, randomized study comparing systemic interferon-α-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis , 2001, American Journal of Gastroenterology.

[133]  L. Mortelmans,et al.  Tc-99m HMPAO White Blood Cell Scintigraphy in the Assessment of the Extent and Severity of an Acute Exacerbation of Ulcerative Colitis , 2001, Clinical nuclear medicine.

[134]  A. Öst,et al.  A reproducible grading scale for histological assessment of inflammation in ulcerative colitis , 2000, Gut.

[135]  A. Sinha,et al.  A gradual dose reduction is needed after 2 weeks of oral prednisolone treatment for ulcerative colitis , 2000 .

[136]  Ardizzone,et al.  Is maintenance therapy always necessary for patients with ulcerative colitis in remission? , 1999, Alimentary pharmacology & therapeutics.

[137]  R. Pounder,et al.  A simple clinical colitis activity index , 1998, Gut.

[138]  G. Porro,et al.  Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial , 1998, American Journal of Gastroenterology.

[139]  Orlando,et al.  Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis , 1998, Alimentary pharmacology & therapeutics.

[140]  P. Gionchetti,et al.  Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis , 1998, Diseases of the colon and rectum.

[141]  T. Matsumoto,et al.  Application of magnifying chromoscopy for the assessment of severity in patients with mild to moderate ulcerative colitis. , 1997, Gastrointestinal endoscopy.

[142]  C. Feyerabend,et al.  Nicotine enemas for active ulcerative colitis—a pilot study , 1997, Alimentary pharmacology & therapeutics.

[143]  K. Batts,et al.  Transdermal Nicotine for Mildly to Moderately Active Ulcerative Colitis , 1997, Annals of Internal Medicine.

[144]  G. Porro,et al.  Sucralfate and hydrocortisone enemas in the treatment of active ulcerative proctitis—a randomized single‐blind comparative study , 1996, Alimentary pharmacology & therapeutics.

[145]  J. Walker-Smith,et al.  Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. , 1996, Journal of pediatric gastroenterology and nutrition.

[146]  D. Kelleher,et al.  Microalbuminuria correlates with intestinal histopathological grading in patients with inflammatory bowel disease. , 1996, Gut.

[147]  R. Modigliani,et al.  Comparison of budesonide and 5‐aminosalicylic acid enemas in active distal ulcerative colitis , 1995, Alimentary pharmacology & therapeutics.

[148]  T. Bayless,et al.  Budesonide enema is an effective alternative to hydrocortisone enema in active distal ulcerative colitis , 1995 .

[149]  L. Påhlman,et al.  Budesonide versus prednisolone retention enemas in active distal ulcerative colitis , 1994, Alimentary pharmacology & therapeutics.

[150]  R. Odze,et al.  Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. , 1993, The American journal of surgical pathology.

[151]  S. Hanauer,et al.  Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. , 1993, The American journal of gastroenterology.

[152]  K. Batts,et al.  Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. , 1993, The American journal of gastroenterology.

[153]  L. Franzén,et al.  Do technetium-99m hexamethylpropylene amine oxime-labeled leukocytes truly reflect the mucosal inflammation in patients with ulcerative colitis? , 1992, Scandinavian journal of gastroenterology.

[154]  P. Munkholm,et al.  Colorectal cancer risk and mortality in patients with ulcerative colitis. , 1992, Gastroenterology.

[155]  T. Yao,et al.  An index of disease activity in patients with ulcerative colitis. , 1992, The American journal of gastroenterology.

[156]  T. Kirchner,et al.  Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. , 1992, Gastroenterology.

[157]  Jacob Cohen,et al.  A power primer. , 1992, Psychological bulletin.

[158]  R A Deyo,et al.  Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. , 1991, Controlled clinical trials.

[159]  S. Riley,et al.  Microscopic activity in ulcerative colitis: what does it mean? , 1991, Gut.

[160]  Ami,et al.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. , 1989, BMJ.

[161]  S. Riley,et al.  Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. , 1988, Gastroenterology.

[162]  C. H. Mason,et al.  Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. , 1988, Scandinavian journal of gastroenterology. Supplement.

[163]  U. von Gaisberg,et al.  [Ulcerative colitis. Activity index for the clinical and histological classification of inflammatory activity]. , 1988, Schweizerische medizinische Wochenschrift.

[164]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[165]  L. Sutherland,et al.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. , 1987, Gastroenterology.

[166]  R. Willén,et al.  Histologic and colonoscopic assessment of disease extension in ulcerative colitis. , 1987, Scandinavian journal of gastroenterology.

[167]  G. Guyatt,et al.  Measuring change over time: assessing the usefulness of evaluative instruments. , 1987, Journal of chronic diseases.

[168]  Å. Danielsson,et al.  A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. , 1987, Scandinavian journal of gastroenterology.

[169]  H. Demonaco,et al.  5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial. , 1986, The American journal of gastroenterology.

[170]  M. Camilleri,et al.  Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. , 1986, Gastroenterology.

[171]  C. Smith,et al.  Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. , 1986, Gut.

[172]  K. Geisinger,et al.  Correlation of histopathologic evidence of disease activity with the presence of immunoglobulin-containing cells in the colons of patients with inflammatory bowel disease. , 1984, Human pathology.

[173]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[174]  V. Binder,et al.  A comparison between clinical state, macroscopic and microscopic appearances of rectal mucosa, and cytologic picture of mucosal exudate in ulcerative colitis. , 1970, Scandinavian journal of gastroenterology.

[175]  J. Goligher,et al.  Sigmoidoscopy and cytology in the detection of microscopic disease of the rectal mucosa in ulcerative colitis , 1966, Gut.

[176]  R. Carpenter,et al.  Controlled trial of sulphasalazine in the treatment of ulcerative colitis , 1964, Gut.

[177]  J. H. Baron,et al.  Variation Between Observers in Describing Mucosal Appearances in Proctocolitis* , 1964, British medical journal.

[178]  Matts Sg,et al.  THE VALUE OF RECTAL BIOPSY IN THE DIAGNOSIS OF ULCERATIVE COLITIS1 , 1961 .

[179]  S. Truelove,et al.  Biopsy Studies in Ulcerative Colitis , 1956, British medical journal.

[180]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .